

Curriculum Vitae

John Tyler Baber, M.D.

Research Affiliation

Elligo Health Research, Inc., 2022- Present
11612 Bee Cave Road, Bldg. 1, Suites 100 & 150, Austin, TX 78738


Research Affiliation

Arkansas Center for Sleep Medicine, PLLC
11219 Financial Centre Parkway, Suite 101
Little Rock, AR 72211
(501) 553-9987
(501) 553-9986 FAX

Research Affiliation

Preferred Research Partners, Inc.
11219 Financial Centre Parkway, Suite 320
Little Rock, AR 72211
(501) 553-9987
(501) 553-9986 FAX

Signature: _____



Date: _____

9/15/2022



Research Affiliation Memo

John Tyler Baber, M.D.

Research Affiliation
Endoscopy Center of Arkansas
1024 North University Avenue
Little Rock, AR 72207

Affiliation Date: January 2009 to present

Signature: _____

A handwritten signature in black ink, appearing to be "J. T. Baber", written over a horizontal line.

Date: _____

A handwritten date "8/2/2022" in black ink, written over a horizontal line.



Research Affiliation Memo

John Tyler Baber, M.D.

Research Affiliation
Radiology Consultants of Little Rock
9601 Baptist Health Drive
Suite 1100
Little Rock, AR 72205

Affiliation Date: January 2009 to present

Signature: _____

A handwritten signature in black ink, appearing to read "J. Tyler Baber", is written over a horizontal line.

Date: _____

2/2/2022



Research Affiliation Memo

John Tyler Baber, M.D.

Research Affiliation
Radiology Consultants of Little Rock, P.A.
900 S. Shackleford Rd.
Suite 110
Little Rock, AR 72211

Affiliation Date: January 2009 to present

Signature: _____

A handwritten signature in black ink, appearing to be "J. Baber", written over a horizontal line.

Date: _____

2/2/2022

John Tyler Baber, M.D.

drbaberp@gmail.com

Education:

University of Arkansas
Fayetteville, Arkansas

University of Arkansas School of Medicine
Little Rock, Arkansas, 1975
Doctor of Medicine

Internship:

Los Angeles County – University of Southern
California Medical Center
Los Angeles, California, 1975-1976

Fellowship:

Rancho Los Amigos Hospital
Downoby, California
DIABETES, 1976-1977

Residency:

LAC-USC Medical Center
Los Angeles, California
INTERNAL MEDICINE, 1977 – 1979

Fellowship:

Baylor College of Medicine
Houston, Texas
GASTROENTEROLOGY, 1979 – 1980

Fellowship:

University of Texas – Health Science Center
Dallas, Texas
HEPATOLOGY, 1980 – 1981

Work Experience:

Solo Practice
Gastroenterology/Hepatology
1981 to Present

Preferred Research Partners, Inc.
Principal Investigator
2009 to Present

Certification/Licensure:

American Board of Internal Medicine
Gastroenterology
American Board of Internal Medicine
Arkansas State Medical Board
California State Medical Board
Texas State Medical Board

Professional Organizations:

Arkansas Medical Society
American Gastroenterology Association
American College of Gastroenterology
American College of Physicians
Arkansas Foundation for Medical Care
President, Arkansas Gut Club, 2001, 2002, 2003

Medicare Carrier Advisory Committee
Arkansas-Oklahoma Endoscopic Society
Chief of Gastroenterology – Baptist Medical Center,
2003 – 2006

Research:

Standard Therapeutic Assessment of Rebetrone Trial - 2000 – 2001

Tegaserod in GI disorders – Novartis - CHTF919E2302, 2001-2002

Tegaserod (HTP919) – Novartis - CHTF919A2306, 2003

Diarrhea-Predominant Irritable Bowel Syndrome (27018966IBS2001) –
Furiex Pharmaceuticals, 2010-2011

Opioid Induced Constipation (D3820C00005) -
AstraZeneca, 2010-2012

Chronic Idiopathic Constipation (LUBI-SGCP-05SB07-CE), Apotex, Inc.,
2011-2011

Opioid Induced Constipation (D3820C00008) – roll-over, AstraZeneca,
2011-2012

Chronic Idiopathic Constipation (71060001) – Anchen, Novum PRS,
2011-2012

Chronic Idiopathic Constipation (SP304-20210) – Synergy
Pharmaceuticals, 2011-2013

Opioid Induced Constipation (1107V9221) – Shionogi, Inc., 2012-2012

Healthy Adult Phase I (SP1031) – UCB, 2012-2012

Diarrhea-Predominant Irritable Bowel Syndrome (27018966IBS3001) –
Furiex Pharmaceuticals, 2012

Diarrhea-Predominant Irritable Bowel Syndrome (LX1033.201-1) –
Lexicon Pharmaceuticals, 2012

Diarrhea-Predominant Irritable Bowel Syndrome (ASMP3001) – Tioga
Pharmaceuticals, 2012-2013

Crohn's Disease (TU100P2T2) – Tsumura, 2012

Crohn's Disease (CNDO201-003) – Coronado Biosciences, 2012

Gastroesophageal Reflux Disease (SPD557-206) – Shire, 2012

Chronic Idiopathic Constipation (DRGL-USG01-L/2012) – Dr. Reddy's
Laboratories, 2012

Chronic Back Pain & Opioid Induced Constipation (ONU3705) – Purdue
Pharma, 2013

Opioid Induced Constipation (5945-SOIC-12-05) – Cubist
Pharmaceuticals, 2013

Chronic Idiopathic Constipation (00080) – Ferring Pharmaceuticals, 2013

Opioid Induced Constipation (5945-OIC-12-04) – Cubist Pharmaceuticals,
2013

Chronic Idiopathic Constipation (00081) – Ferring Pharmaceuticals, 2013

Diarrhea-Predominant Irritable Bowel Syndrome (NAK-07) – Menarini
Pharmaceuticals, 2013

Chronic Idiopathic Constipation (CIC) – Synergy Pharmaceuticals, Inc. –
SP304203-01 (CIC-OLE), 2013

Opioid-induced Constipation in Subjects with Non-malignant Chronic
Pain Receiving Opioid Therapy – Shionogi, Inc. – 1315V9232, 2013

Chronic Idiopathic Constipation – Synergy Pharmaceuticals, Inc. –
SP304203-00 (CIC3), 2013

Diabetic Gastroparesis – Evoke Pharma – METO-IN-003, 2014

Diabetic Gastroparesis – Evoke Pharma – METO-IN-004, 2014

Incidence of Major Adverse Cardiovascular Events and Conversion to
Type 2 Diabetes Mellitus in Obese and Overweight Subjects with
Cardiovascular Disease or Multiple Cardiovascular Risk – Eisai Inc. –
APD356-G000-401 (CAMELLIA), 2014

Active Moderate Crohn's Disease – Salix Pharmaceuticals, Inc. –
RECD3125, 2014

Gastric Emptying Time in Diabetic Subjects with Gastroparesis –
Targacept – TC-6499-12-CLP-005, 2014

Diabetic Gastroparesis – Rhythm Pharmaceuticals – RM-131-009, 2015

Diabetic or Idiopathic Gastroparesis – Theravance– 0099, 2015

Irritable Bowel Syndrome-Constipation – Synergy Pharmaceuticals, Inc. –
SP304203-04, 2015

Irritable Bowel Syndrome-Constipation &/or Chronic Idiopathic
Constipation – Forest Research Institute, Inc. – LIN-MD-10, 2015

Ulcerative Colitis – Gilead – GS-US-326-1100, 2015

Ferring International Pharmascience Center US, Inc., Ulcerative Colitis – 000174, 2016

Ferring International Pharmascience Center US, Inc., Ulcerative Colitis – 000175, 2016

Conatus Pharmaceuticals, Non-alcoholic Steatohepatitis (NASH) – IDN-6556-12, 2016

Synergy Pharmaceuticals, Irritable Bowel Syndrome with Constipation (IBS-C) – SP304203-06, 2016

Luitpold Pharmaceuticals, Inc., Restless Legs Syndrome – 1VIT14037, 2016

Braintree Laboratories, Chronic Constipation – BLI400-302, 2016

Braintree Laboratories, Opioid Induced Constipation – BLI801-203, 2016

Applied Proteomics – Colorectal Cancer Screening – API-CP001, 2016

Takeda Pharmaceuticals – Diabetic or Idiopathic Gastroparesis – TAK906-1002, 2017

Allergan – Diabetic Gastroparesis – RLM-MD-01, 2017

Braintree Laboratories, Bowel Prep for Colonoscopy – BLI4700-302, 2017

Vanda Pharmaceuticals, Inc. – Diabetic or Idiopathic Gastroparesis – VP-VLY-686-2301, 2017

Allergan – Diabetic Gastroparesis – RLM-MD-04, 2017

Freenome Holdings, Inc., Health Decisions – Colorectal Cancer Screening, FRE-001, 2018

Allergan – Diabetic Gastroparesis – RLM-MD-03, 2018

2018: Allergan – Diabetic Gastroparesis – 3071-305-020

2018: Ironwood Pharmaceuticals – GERD – C3718-302

2019: Adare Pharmaceuticals – Eosinophilic Erosive Esophagitis – SP-1011-003

2019: Allergan - Liver Fibrosis in Adult Subjects with Nonalcoholic Steatohepatitis – 3152-301-002

2019: Allergan – Constipation in Children 6-17 y/o – LIN-MD-64

2019: Allergan – Pediatric Participants with Functional Constipation (FC) or Irritable Bowel Syndrome with Constipation (IBS-C) – LIN-MD-66

2019: Allergan - Pediatric Participants (Age 2 to 5 Years) with Functional Constipation – LIN-MD-67

2019: Braintree Laboratories - Bowel Prep for Colonoscopy – BLI4900-302

2019: Phathom Pharmaceuticals – Erosive Esophagitis – EE-301

2019: Phathom Pharmaceuticals – H. Pylori – HP-301

2019: Vanda Pharmaceuticals – Diabetic or Idiopathic Gastroparesis – VP-VLY-686-3301

2019: Vibrant Ltd – Chronic Idiopathic Constipation – V270

2019: OrphoMed – Diarrhea-predominant Irritable Bowel Syndrome (IBS-D) – OM-201

2020: Neurogastrx – Diabetic or Idiopathic Gastroparesis – NG101-201

2020: Guardant Health – Colorectal Cancer Screening – 02-GI-002
ECLIPSE

2021: Phathom Pharmaceuticals – Non-erosive Reflux Disease – NERD-201

2021: Revolo Pharmaceuticals – Eosinophilic Esophagitis – RVLO 121-04

2022: 89 Bio – NASH – BIO89-100-122

2022: Phathom Pharmaceuticals – Non-erosive Reflux Disease – NERD-301

Personal:

Name – John Tyler Baber, M.D.
Birthplace – St. Louis, Missouri
Birth Date – June 26, 1950
Email – drbaberprp@gmail.com

Business Address:

CHI St. Vincent Gastroenterology Clinic – Little Rock
417 North University
Little Rock, AR 72205

Preferred Research Partners, Inc.
11219 Financial Center Parkway
Suite 320
Little Rock, AR 72211